A retrospective survey of patients with malignant gliomas treated in the neuro-oncological care system under the Universal National Health Insurance program in Taiwan

Yin Cheng Huang, Kuo Chen Wei, Chin Hong Chang, Jen Tsung Yang, Jih Tsun Ho, Chiung Chyi Shen, Chain Fa Su, Der Yang Cho, Hsin I. Ma, Jia Wei Lin, E. Jian Lee, Jionn Jong Wu, Ming Dar Tsai, Cheng Kuei Chang, Shen Long Howng, Chen Nen Chang

研究成果: 雜誌貢獻文章

6 引文 (Scopus)

摘要

In 1995 a government-supported Universal National Health care system was implemented in Taiwan, which in 2008 was available to 98% of the population. This system offers affordable, rapid medical attention. A multi-center retrospective study was conducted to assess the prognosis of malignant glioma patients under this system. In 2005 and 2006, patients at 14 independent neuro-oncology centers with newly diagnosed malignant glioma were enrolled. The patient profile, pathology, treatment modalities, and prognosis were collected by questionnaire at each center. The Taiwan Neuro-Oncology Society was responsible for the data analysis. The overall median survival period, 1-year survival rate, and 2-year survival rate for patients with World Health Organization grade III glioma were 33.8 months, 81.4%, and 58.2%, respectively, and 15 months, 57.3%, and 33.9% in patients with grade IV glioma. The median survival period, 1-year survival rate, and 2-year-survival rate in patients receiving temozolomide adjuvant therapy was 36 months, 84.2%, and 61.8%, respectively, for patients with grade III glioma and 19.8 months, 73.1%, and 43.7%, for patients with grade IV glioma. The universal health care system in Taiwan offers a comparable prognosis with an affordable premium relative to other large series in developed countries.
原文英語
頁(從 - 到)784-788
頁數5
期刊Journal of Clinical Neuroscience
18
發行號6
DOIs
出版狀態已發佈 - 六月 2011

指紋

National Health Programs
Taiwan
Glioma
Survival Rate
temozolomide
Delivery of Health Care
Survival
Surveys and Questionnaires
Developed Countries
Retrospective Studies
Pathology
Therapeutics
Population

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Physiology (medical)

引用此文

A retrospective survey of patients with malignant gliomas treated in the neuro-oncological care system under the Universal National Health Insurance program in Taiwan. / Huang, Yin Cheng; Wei, Kuo Chen; Chang, Chin Hong; Yang, Jen Tsung; Ho, Jih Tsun; Shen, Chiung Chyi; Su, Chain Fa; Cho, Der Yang; Ma, Hsin I.; Lin, Jia Wei; Lee, E. Jian; Wu, Jionn Jong; Tsai, Ming Dar; Chang, Cheng Kuei; Howng, Shen Long; Chang, Chen Nen.

於: Journal of Clinical Neuroscience, 卷 18, 編號 6, 06.2011, p. 784-788.

研究成果: 雜誌貢獻文章

Huang, YC, Wei, KC, Chang, CH, Yang, JT, Ho, JT, Shen, CC, Su, CF, Cho, DY, Ma, HI, Lin, JW, Lee, EJ, Wu, JJ, Tsai, MD, Chang, CK, Howng, SL & Chang, CN 2011, 'A retrospective survey of patients with malignant gliomas treated in the neuro-oncological care system under the Universal National Health Insurance program in Taiwan', Journal of Clinical Neuroscience, 卷 18, 編號 6, 頁 784-788. https://doi.org/10.1016/j.jocn.2010.10.016
Huang, Yin Cheng ; Wei, Kuo Chen ; Chang, Chin Hong ; Yang, Jen Tsung ; Ho, Jih Tsun ; Shen, Chiung Chyi ; Su, Chain Fa ; Cho, Der Yang ; Ma, Hsin I. ; Lin, Jia Wei ; Lee, E. Jian ; Wu, Jionn Jong ; Tsai, Ming Dar ; Chang, Cheng Kuei ; Howng, Shen Long ; Chang, Chen Nen. / A retrospective survey of patients with malignant gliomas treated in the neuro-oncological care system under the Universal National Health Insurance program in Taiwan. 於: Journal of Clinical Neuroscience. 2011 ; 卷 18, 編號 6. 頁 784-788.
@article{e4abcde9766c4831b072d81cca08b684,
title = "A retrospective survey of patients with malignant gliomas treated in the neuro-oncological care system under the Universal National Health Insurance program in Taiwan",
abstract = "In 1995 a government-supported Universal National Health care system was implemented in Taiwan, which in 2008 was available to 98{\%} of the population. This system offers affordable, rapid medical attention. A multi-center retrospective study was conducted to assess the prognosis of malignant glioma patients under this system. In 2005 and 2006, patients at 14 independent neuro-oncology centers with newly diagnosed malignant glioma were enrolled. The patient profile, pathology, treatment modalities, and prognosis were collected by questionnaire at each center. The Taiwan Neuro-Oncology Society was responsible for the data analysis. The overall median survival period, 1-year survival rate, and 2-year survival rate for patients with World Health Organization grade III glioma were 33.8 months, 81.4{\%}, and 58.2{\%}, respectively, and 15 months, 57.3{\%}, and 33.9{\%} in patients with grade IV glioma. The median survival period, 1-year survival rate, and 2-year-survival rate in patients receiving temozolomide adjuvant therapy was 36 months, 84.2{\%}, and 61.8{\%}, respectively, for patients with grade III glioma and 19.8 months, 73.1{\%}, and 43.7{\%}, for patients with grade IV glioma. The universal health care system in Taiwan offers a comparable prognosis with an affordable premium relative to other large series in developed countries.",
keywords = "Chemotherapy, Malignant glioma, Radiation therapy, Surgery, Universal health insurance",
author = "Huang, {Yin Cheng} and Wei, {Kuo Chen} and Chang, {Chin Hong} and Yang, {Jen Tsung} and Ho, {Jih Tsun} and Shen, {Chiung Chyi} and Su, {Chain Fa} and Cho, {Der Yang} and Ma, {Hsin I.} and Lin, {Jia Wei} and Lee, {E. Jian} and Wu, {Jionn Jong} and Tsai, {Ming Dar} and Chang, {Cheng Kuei} and Howng, {Shen Long} and Chang, {Chen Nen}",
year = "2011",
month = "6",
doi = "10.1016/j.jocn.2010.10.016",
language = "English",
volume = "18",
pages = "784--788",
journal = "Journal of Clinical Neuroscience",
issn = "0967-5868",
publisher = "Churchill Livingstone",
number = "6",

}

TY - JOUR

T1 - A retrospective survey of patients with malignant gliomas treated in the neuro-oncological care system under the Universal National Health Insurance program in Taiwan

AU - Huang, Yin Cheng

AU - Wei, Kuo Chen

AU - Chang, Chin Hong

AU - Yang, Jen Tsung

AU - Ho, Jih Tsun

AU - Shen, Chiung Chyi

AU - Su, Chain Fa

AU - Cho, Der Yang

AU - Ma, Hsin I.

AU - Lin, Jia Wei

AU - Lee, E. Jian

AU - Wu, Jionn Jong

AU - Tsai, Ming Dar

AU - Chang, Cheng Kuei

AU - Howng, Shen Long

AU - Chang, Chen Nen

PY - 2011/6

Y1 - 2011/6

N2 - In 1995 a government-supported Universal National Health care system was implemented in Taiwan, which in 2008 was available to 98% of the population. This system offers affordable, rapid medical attention. A multi-center retrospective study was conducted to assess the prognosis of malignant glioma patients under this system. In 2005 and 2006, patients at 14 independent neuro-oncology centers with newly diagnosed malignant glioma were enrolled. The patient profile, pathology, treatment modalities, and prognosis were collected by questionnaire at each center. The Taiwan Neuro-Oncology Society was responsible for the data analysis. The overall median survival period, 1-year survival rate, and 2-year survival rate for patients with World Health Organization grade III glioma were 33.8 months, 81.4%, and 58.2%, respectively, and 15 months, 57.3%, and 33.9% in patients with grade IV glioma. The median survival period, 1-year survival rate, and 2-year-survival rate in patients receiving temozolomide adjuvant therapy was 36 months, 84.2%, and 61.8%, respectively, for patients with grade III glioma and 19.8 months, 73.1%, and 43.7%, for patients with grade IV glioma. The universal health care system in Taiwan offers a comparable prognosis with an affordable premium relative to other large series in developed countries.

AB - In 1995 a government-supported Universal National Health care system was implemented in Taiwan, which in 2008 was available to 98% of the population. This system offers affordable, rapid medical attention. A multi-center retrospective study was conducted to assess the prognosis of malignant glioma patients under this system. In 2005 and 2006, patients at 14 independent neuro-oncology centers with newly diagnosed malignant glioma were enrolled. The patient profile, pathology, treatment modalities, and prognosis were collected by questionnaire at each center. The Taiwan Neuro-Oncology Society was responsible for the data analysis. The overall median survival period, 1-year survival rate, and 2-year survival rate for patients with World Health Organization grade III glioma were 33.8 months, 81.4%, and 58.2%, respectively, and 15 months, 57.3%, and 33.9% in patients with grade IV glioma. The median survival period, 1-year survival rate, and 2-year-survival rate in patients receiving temozolomide adjuvant therapy was 36 months, 84.2%, and 61.8%, respectively, for patients with grade III glioma and 19.8 months, 73.1%, and 43.7%, for patients with grade IV glioma. The universal health care system in Taiwan offers a comparable prognosis with an affordable premium relative to other large series in developed countries.

KW - Chemotherapy

KW - Malignant glioma

KW - Radiation therapy

KW - Surgery

KW - Universal health insurance

UR - http://www.scopus.com/inward/record.url?scp=79955905732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955905732&partnerID=8YFLogxK

U2 - 10.1016/j.jocn.2010.10.016

DO - 10.1016/j.jocn.2010.10.016

M3 - Article

C2 - 21507649

AN - SCOPUS:79955905732

VL - 18

SP - 784

EP - 788

JO - Journal of Clinical Neuroscience

JF - Journal of Clinical Neuroscience

SN - 0967-5868

IS - 6

ER -